[3] Rastogi P, et al. J Clin Oncol. 2024;42(9):987-993. [4] Pan H, et al. N Engl J Med. 2017 Nov 9;377(19):1836-1846. [5] Giuseppe Curigliano, et al. 2024 ASCO. Abstract 541. [6] Pedram Raz...
At the 2024 ASCO, Henlius will release the extended follow-up results and patient-reported outcomes from the pivotal phase 3 clinical study (ASTRUM-005) of serplulimab for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) with Professor Ying Cheng from Jilin Cancer...
Eric Small教授提到,今年ASCO年会是历届规模最大、参会人数最多的一届,来自全球的肿瘤领域研究进展齐放异彩,尤其是来自中国研究者的报告也在本次会议中占据重要地位——在今年ASCO全体大会系列专场Updates of the Abstract环节的6项重磅研究...
NEW YORK, May 23, 2024 /PRNewswire/ -- Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that the American Society of Clinical Oncology (ASCO) has published an abstract in ...
第二项研究为SKB264+KL-A167联合一线治疗晚期非小细胞肺癌二期临床OptiTROP-Lung01的最新数据,将于美国当地时间5月31日下午2:45-5:45在“Oral Abstract Session-Lung Cancer- Non-Small cell Metastatic” Session进行口头报告。 SKB264由科伦博泰基于其OptiDC技术平台自主开发,采用了独特的差异化设计,由高亲和力的...
Abstract 105 BRCA1/2突变转移性去势抵抗性前列腺癌(mCRPC)接受尼拉帕利(NIRA)联合醋酸阿比特龙和泼尼松(AAP)治疗的患者报告结局:来自MAGNITUDE研究的结果 背景: MAGNTITUDE是一项国际3期随机双盲研究,研究表明与安慰剂(PBO) AAP相比,接受NIRA AAP治疗的BRCA1/2突变的mCRPC患者,其影像学无进展生存期显著提高,并在症状...
2024年美国临床肿瘤学会(ASCO)年会将于5月31日到6月4日在芝加哥举办,是世界上规模最大、学术水平最高、最具权威性的临床肿瘤学会议,会议汇集了全球肿瘤学医生和专业人士、患者倡导者、工业界代表和主要媒体,共同探讨当前国际最前沿的研究发现和临床试验成果。
其二是SKB264联合PD-L1单抗KL-A167一线治疗晚期非小细胞肺癌的临床二期OptiTROP-Lung01研究的最新数据（NCT05351788），将于Oral Abstract Session口头汇报，摘要号为8502。ADC+IO正在开启肿瘤免疫治疗新时代之际，科伦博泰也在积极布局。可见，成功牵手默沙东，并作为默沙东肿瘤管线未来的重要产品之一，SKB264正在国际舞台...
Key data from Merck’s pipeline to be presented at ASCO 2024: First presentation of three-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940) in combination with KEYTRUDA as adj...
Oral Abstract Session -Sarcoma 6/3/2024 3:00 PM -6:00 PM Dr. Zhiguo Luo Updated survival results of BBCAPX-II: sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic c...